CRL
Charles River Laboratories
NYSE: CRL · HEALTHCARE · DIAGNOSTICS & RESEARCH
$166.97
+1.91% today
Updated 2026-04-30
Market cap
$8.23B
P/E ratio
—
P/S ratio
2.05x
EPS (TTM)
$-2.90
Dividend yield
—
52W range
$114 – $229
Volume
0.9M
Charles River Laboratories (CRL) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.54B | $2.56B | $2.81B | $2.16B | $2.20B | $1.73B | $1.56B | $1.59B | $1.64B | $1.89B | $2.07B | $2.71B | $2.93B | $3.86B | $4.69B | $5.49B | $7.02B | $7.60B | $8.20B | $7.53B |
| Cash & equivalents | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current assets | $419.32M | $501.09M | $607.86M | $618.14M | $595.60M | $552.89M | $425.84M | $485.25M | $552.55M | $606.90M | $559.23M | $656.83M | $826.63M | $897.84M | $1.02B | $1.20B | $1.27B | $1.44B | $1.61B | $1.40B |
| Total liabilities | $701.48M | $953.11M | $941.57M | $960.47M | $830.27M | $1.04B | $1.03B | $983.14M | $979.96M | $1.18B | $1.30B | $1.86B | $1.87B | $2.52B | $3.03B | $3.35B | $4.43B | $4.58B | $4.54B | $4.02B |
| Current liabilities | $311.41M | $259.33M | $302.53M | $301.00M | $249.77M | $259.78M | $216.80M | $342.25M | $247.03M | $296.17M | $311.76M | $429.59M | $463.50M | $558.22M | $710.18M | $839.75M | $1.03B | $1.09B | $1.06B | $994.10M |
| Long-term debt | $260.22M | $547.08M | $485.00M | $540.65M | $457.42M | $670.27M | $703.19M | $527.14M | $642.35M | $745.96M | $846.00M | $1.21B | $1.11B | $1.64B | $1.82B | $1.90B | $2.64B | $2.71B | $2.65B | $2.24B |
| Shareholder equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Retained earnings | $78.91M | $23.12M | $177.53M | $-344.31M | $-238.49M | $-575.16M | $-465.60M | $-368.30M | $-265.47M | $-138.78M | $10.54M | $165.30M | $288.66M | $42.10M | $280.33M | $625.41M | $980.75M | $1.43B | $1.89B | $1.81B |
| Accounts receivable | $171.26M | $202.66M | $213.91M | $210.21M | $196.95M | $192.97M | $184.81M | $203.00M | $220.63M | $257.99M | $270.07M | $364.05M | $430.02M | $472.25M | $514.03M | $617.74M | $650.38M | $752.39M | $780.38M | $720.91M |
| Inventory | $65.27M | $72.36M | $88.02M | $96.88M | $102.72M | $100.30M | $92.97M | $88.47M | $89.40M | $89.04M | $93.73M | $95.83M | $114.96M | $127.89M | $160.66M | $185.69M | $199.15M | $255.81M | $380.26M | $278.54M |
| Goodwill | $1.10B | $1.12B | $1.12B | $457.58M | $508.24M | $198.44M | $197.56M | $208.61M | $230.70M | $321.08M | $438.83M | $787.52M | $804.91M | $1.25B | $1.54B | $1.81B | $2.71B | $2.85B | $3.10B | $2.85B |